Recap: Mersana Therapeutics Q2 Earnings

Shares of Mersana Therapeutics MRSN remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share were up 8.33% year over year to ($0.33), which missed the estimate of ($0.30).

Revenue of $796,000 rose by 294.06% year over year, which beat the estimate of $300,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 07, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/wytvxume

Price Action

52-week high: $24.97

52-week low: $1.32

Price action over last quarter: Up 110.81%

Company Overview

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.